Clinical Cancer Research · 2014 · 53 citations · 54 references
Life SciencesMolecular BiologyOncologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingOncogenic Signaling PathwaysSignal Transduction In CancerSmall Gtpase SignalingTargeted Cancer TherapyDownstream Kinase ActivationMolecular SwitchesOncogenic TransformationRac1 SignalingRegulation By Small GtpasesRho Family Gtpase SignalingRho Family GtpasesSmall Rho Gtpase Signaling
RHO GTPases, members of the RAS superfamily of small GTPases, are adhesion and growth factor-activated molecular switches that play important roles in tumor development and progression. When activated, RHO-family GTPases such as RAC1, CDC42, and RHOA, transmit signals by recruiting a variety of effector proteins, including the protein kinases PAK, ACK, MLK, MRCK, and ROCK. Genetically induced loss of RHO function impedes transformation by a number of oncogenic stimuli, leading to an interest in developing small-molecule inhibitors that either target RHO GTPases directly, or that target their downstream protein kinase effectors. Although inhibitors of RHO GTPases and their downstream signaling kinases have not yet been widely adopted for clinical use, their potential value as cancer therapeutics continues to facilitate pharmaceutical research and development and is a promising therapeutic strategy.
54
A small molecule–kinase interaction map for clinical kinase inhibitors
Miles A. Fabian, William Biggs, Daniel K. Treiber et al. · Nature Biotechnology · 2005 · 1.9K citations · Full text
Louis J. Lombardo, Francis Y. Lee, Ping Chen et al. · Journal of Medicinal Chemistry · 2004 · 1.3K citations · Full text
Medicine, Oncology, Pharmacology +13